SHR0410 (Hengrui Pharmaceutical)

SHR0410 is an investigational, potent, and selective small molecule inhibitor of AKT (protein kinase B) isoforms 1, 2, and 3, developed by Jiangsu Hengrui Pharmaceuticals. It is currently being evaluated in a Phase II precision platform study (NCT05511012) led by Fudan University, which utilizes Similarity Network Fusion (SNF) molecular subtyping to guide therapy in patients with HR+/HER2- advanced breast cancer who have progressed on CDK4/6 inhibitors. SHR0410 is specifically assigned to the SNF-2 (metabolic) subtype, which is characterized by genomic alterations in the PI3K/AKT/mTOR pathway. By inhibiting AKT, the drug aims to block signaling pathways that drive tumor cell survival, proliferation, and resistance to endocrine therapy.

Other names

AKT inhibitorAKT inhibitor-Fudan University-breast cancer (HR+/HER2- advanced)